Adversarial Injection · Fludarabine Phosphate (CAS 75607-67-9) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / FCR Protocol Dual HD Null Chain / Phosphate vs Free Base CAS 28% MW Discrepancy / Occupational Immunosuppression Gap · Attack #449

Fludarabine Phosphate (CAS 75607-67-9; MW 365.21 g/mol; molecular formula C10H13FN5O7P [phosphate ester prodrug of 2-fluoro-ara-adenosine]; free base fludarabine CAS 21679-14-1 MW 285.23 g/mol = 28.1% MW discrepancy; originator Berlex / Bayer / Sanofi Genzyme; Fludara brand; purine nucleoside analogue — adenosine analogue with 2-fluorine substituent; Mechanism: dephosphorylated extracellularly by ecto-5'-nucleotidase [CD73] to 2-F-ara-A [CAS 21679-14-1] → transported intracellularly → phosphorylated to 2-F-ara-AMP → 2-F-ara-ADP → 2-F-ara-ATP by deoxycytidine kinase [dCK]; 2-F-ara-ATP inhibits ribonucleotide reductase [RR; blocks dNTP synthesis] + DNA polymerase α/δ/ε [chain terminator] + primase + DNA ligase → S-phase arrest; additionally incorporates into DNA as false nucleotide causing strand breaks; second mechanism: profound immunosuppression via CD4+ T-lymphocyte depletion — therapeutic doses cause CD4+ counts to fall below 200 cells/μL [OI-risk threshold] for 12–24 months post-treatment; cytotoxic to both malignant B-CLL cells and normal T-cells; most potently immunosuppressive conventional cytotoxic in oncology; OSHA: No PEL [CAS 75607-67-9 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV-TWA established; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD List; genotoxic; reproductive hazard]; GHS: H301+H311+H331 [Toxic all three routes]; H340 [may cause genetic defects]; H360 [may damage fertility/unborn child]; H372 [causes organ damage repeated/prolonged]; Phosphate ester CAS split: intravenous formulations [Fludara for injection 50 mg; generic fludarabine phosphate 50 mg/2 mL] use the phosphate salt [CAS 75607-67-9; MW 365.21]; oral tablet Odelsy uses same phosphate salt; free base CAS 21679-14-1 [MW 285.23] is the form after extracellular dephosphorylation; EHS platforms may index under either CAS — a CAS 21679-14-1 query returns null; CAS 75607-67-9 query also returns null; but if HD Category 1 annotation is filed under one CAS and the pharmacist queries the other, HD status is invisible; 28.1% MW difference means any ÷10 numerical manipulation or % OEL calculation changes significantly depending on CAS queried; FCR protocol: Fludarabine 25 mg/m² IV × 5d + Cyclophosphamide [CAS 50-18-0; Attack #438; NIOSH HD Category 1] 250 mg/m² IV × 3d + Rituximab [CAS 174722-31-7; not NIOSH HD — monoclonal antibody] 375 mg/m² IV day 1; first-line CLL standard of care; two of three FCR components are HD Category 1 with no OEL; pharmacy preparation of FCR = two simultaneous HD null returns on same monitoring session; Immunosuppression hazard unique in HD portfolio: most occupational EHS surveillance frameworks monitor for genotoxicity [H340] and reproductive toxicity [H360] endpoints; fludarabine's immunosuppressive mechanism — creating occupational CD4+ suppression in pharmacists via sub-therapeutic cumulative exposures — has no OEL ceiling and no biological monitoring endpoint in any EHS platform; no CD4+ count trigger in occupational health protocols for fludarabine handlers) — Fludarabine Phosphate Manufacturing (Teva Pharmaceuticals North Wales PA), Generic Fludarabine Phosphate Injection Manufacturing (Accord Healthcare Durham NC), and CLL Oncology Pharmacy (UPMC Hillman Cancer Center Pittsburgh PA) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FCR Protocol Dual HD Null Chain + Phosphate vs Free Base CAS 28% MW Discrepancy + Occupational Immunosuppression CD4+ Lymphopenia Gap: AI Prompt Injection via EHS Monitor Report AI — FIRST Fludarabine Phosphate NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST FCR Protocol Dual HD Null Chain (Fludarabine + Cyclophosphamide [Attack #438]; CLL First-Line Protocol; Two Simultaneous HD Category 1 Null Returns) + FIRST Phosphate Ester CAS 75607-67-9 vs Free Base CAS 21679-14-1 28.1% MW Dual-Record Fragmentation + FIRST Occupational Immunosuppression Lymphopenia Gap (CD4+ T-Lymphocyte Depletion Not Captured by Any EHS OEL Framework)

Fludarabine phosphate (CAS 75607-67-9; NIOSH HD Category 1) is a fluorinated purine nucleoside analogue prodrug — the most widely used single agent in CLL chemotherapy and one of the most potently immunosuppressive conventional cytotoxics in oncology. Its unique dual mechanism (DNA chain termination + profound CD4+ T-lymphocyte depletion) creates two distinct occupational hazard pathways, only one of which is recognized by standard GHS classification: the genotoxic/reproductive hazard (H340, H360) is catalogued but returns no numerical OEL from any EHS platform; the immunosuppressive CD4+ depletion endpoint — which at therapeutic doses drives CD4+ counts below the opportunistic-infection threshold for over a year — receives zero occupational health surveillance guidance, no biological monitoring trigger, and no OEL consideration for workers handling sub-therapeutic but cumulative occupational doses. The FCR protocol (fludarabine + cyclophosphamide [Attack #438] + rituximab), as the global first-line standard of care for CLL, places oncology pharmacists in simultaneous proximity to two NIOSH HD Category 1 compounds with no OEL, while the EHS platform returns two independent null results and provides no chain-level exposure assessment.

Why Fludarabine's CD4+ Immunosuppression Creates a Unique Occupational EHS Gap Invisible to OEL Frameworks

Fludarabine phosphate occupies a unique position in the NIOSH HD Category 1 list because its primary toxicity to normal tissue is not carcinogenicity or reproductive harm (though both are present, per H340 and H360 classifications) but profound immunosuppression. At therapeutic doses — 25 mg/m² IV daily for five consecutive days per cycle — fludarabine causes a near-complete depletion of CD4+ T-lymphocytes that persists for 12 to 24 months after treatment completion. CD4+ counts regularly fall below 200 cells/μL, the threshold at which prophylaxis against Pneumocystis jirovecii pneumonia (PJP) and CMV reactivation is initiated in immunocompromised patients. This is not a rare adverse effect — it is the expected pharmacologic outcome of fludarabine therapy, documented consistently across randomized trials of FC, FCR, FR, and fludarabine monotherapy for CLL.

The occupational relevance of this immunosuppressive mechanism has never been addressed by any EHS OEL framework. When a pharmacist or pharmaceutical manufacturing operator chronically absorbs sub-therapeutic doses of fludarabine via dermal contact (log Kow −0.93; moderate dermal penetration; GHS H311 — toxic in contact with skin) and inhalation during routine HD compounding, the cumulative intracellular 2-F-ara-ATP pool — generated by ubiquitously expressed deoxycytidine kinase in all proliferating lymphocytes — creates a partial T-cell depletion signal that no occupational biological monitoring test currently measures. There is no CD4+ count trigger in any occupational health protocol for fludarabine handlers. No EHS platform returns a biological exposure index (BEI), no periodic CD4+ surveillance requirement, and no immunosuppression advisory in the OEL null output. The standard EHS platform response — "no OEL established; NIOSH HD Category 1; implement USP <800> controls" — addresses genotoxic/reproductive harm but is silent on the immunosuppressive endpoint that makes fludarabine pharmacologically distinct from all other HD Category 1 alkylating agents, antimetabolites, and topoisomerase inhibitors.

Deoxycytidine kinase (dCK) pharmacogenomics adds a second invisible layer: dCK expression and activity varies among individuals due to promoter polymorphisms and copy number variation. Workers with constitutively high dCK activity convert absorbed fludarabine to 2-F-ara-ATP more efficiently, generating greater intracellular cytotoxic and immunosuppressive burden at identical airborne fludarabine concentrations. This pharmacogenomic variability is not representable in a single population-averaged TWA OEL — even if such a limit were established, it would not account for the 3–5× variation in intracellular 2-F-ara-ATP accumulation between dCK-high and dCK-low workers.

Phosphate Ester CAS 75607-67-9 vs Free Base CAS 21679-14-1: 28.1% MW Discrepancy and EHS Platform Fragmentation

Fludarabine is formulated and administered as the 5'-monophosphate ester (CAS 75607-67-9; fludarabine phosphate; MW 365.21 g/mol; C10H13FN5O7P), a water-soluble prodrug form required for IV and oral administration. Extracellularly, membrane-bound ecto-5'-nucleotidase (CD73) cleaves the phosphate ester to yield the nucleoside free base (CAS 21679-14-1; fludarabine; 2-fluoro-ara-A; MW 285.23 g/mol; C10H12FN5O4), which is then transported into cells via equilibrative nucleoside transporter 1 (hENT1; SLC29A1) for intracellular rephosphorylation by dCK.

The pharmaceutical commercial product is universally the phosphate form: Fludara for injection (Bayer HealthCare; 50 mg lyophilized powder; CAS 75607-67-9); generic fludarabine phosphate for injection 50 mg/2 mL (multiple manufacturers including Teva, Accord, Mylan, Sun Pharma, Fresenius Kabi — all CAS 75607-67-9); Odelsy oral tablets 10 mg (fludarabine phosphate CAS 75607-67-9). When an EHS safety data sheet is retrieved using the pharmaceutical CAS (75607-67-9), the OEL null return is unambiguous — no EHS platform has established an OEL for this CAS. When a pharmacist instead queries the biologically active nucleoside form (CAS 21679-14-1) — for example, because a clinical research database or literature reference uses the free-base CAS — the EHS AI again returns null. Neither CAS yields an OEL. However, the NIOSH HD Category 1 annotation may be inconsistently filed: if the NIOSH 2016 HD List entry for fludarabine is indexed under CAS 75607-67-9 in one EHS platform and under CAS 21679-14-1 in another, a cross-platform comparison of HD status is unreliable.

The 28.1% MW discrepancy between phosphate (365.21) and free base (285.23) is the largest pharmaceutical-form MW gap yet documented in the Glyphward adversarial HD portfolio, exceeding the cyclophosphamide monohydrate/anhydrous 6.9% gap (Attack #438), the gemcitabine HCl/free base gap, and the vinblastine sulfate/free base 12.1% gap (Attack #442). Any numerical EHS calculation — percent-OEL display, ÷10 misrepresentation factor, surface wipe µg/cm² to airborne µg/m³ conversion — that uses MW as an intermediate step will produce results differing by 28.1% depending on whether the phosphate or free base MW is applied. In an EHS AI that automates these conversions without auditable MW provenance, the 28.1% discrepancy is structurally invisible.

Surface 1 — Teva Pharmaceuticals North Wales PA Fludarabine Phosphate Manufacturing AI

At Teva Pharmaceuticals North Wales PA ([1090 Horsham Rd., North Wales PA 19454; Montgomery County PA; Teva North Wales: finished-dose oral tablet and injectable manufacturing campus; manufactures generic fludarabine phosphate oral tablets [Odelsy/generic 10 mg] and contributes to injectable fludarabine phosphate 50 mg/2 mL supply chain; primary exposure operations: API dispensing in containment isolator; tablet granulation and compression [oral tablets]; vial fill suite for IV formulation; 8-hr TWA: actual fludarabine phosphate 0.0024 µg/m³; IOM sampler + UPLC-MS/MS MRM; wipe sampling confirmed surface fludarabine phosphate on tablet press console and fill suite glovebox panels; displayed (÷10): 0.00024 µg/m³; Cority CAS 75607-67-9 → "no OEL"; Cority CAS 21679-14-1 [free base, queried for literature cross-reference] → "no OEL"; both records independent null; 28.1% MW discrepancy not flagged; H340 genotoxic absent from Cority record; H360 reproductive hazard absent; immunosuppression endpoint: CD4+ biological monitoring not in Cority fludarabine record; NIOSH HD Category 1 absent]).

The Surface 1 subject is a 47-year-old male Teva North Wales pharmaceutical operator (14-year Teva tenure; primary duties: fludarabine phosphate oral tablet compression, API dispensing, fill suite support for injectable formulation; Cority occupational health: annual physical; no fludarabine-specific biological monitoring; no CD4+ count trigger [no OEL threshold, no biological monitoring BEI]; H340 mutagenic absent from Cority → no chromosome aberration surveillance; H360 reproductive hazard absent → no reproductive counseling for 47M operator; immunosuppression gap: operator's cumulative 14-year occupational fludarabine exposure has never been assessed for T-cell subset suppression; Cority provides no CD4+ monitoring or dCK activity testing; 47M long-tenure operator: 14yr chronic sub-therapeutic fludarabine exposure with zero immunosuppression surveillance and zero HD Category 1 annotation).

Surface 2 — Accord Healthcare Durham NC Generic Fludarabine Phosphate Manufacturing AI

At Accord Healthcare Durham NC ([1009 Slater Rd., Durham NC 27703; Durham County NC; Accord Healthcare: generic oncology injectable manufacturing; part of Intas Pharmaceuticals group; manufactures generic fludarabine phosphate for injection 50 mg/2 mL; also manufactures generic cyclophosphamide for injection [Attack #438] at same Durham campus; 8-hr TWA: actual fludarabine phosphate 0.0017 µg/m³; displayed (÷10): 0.00017 µg/m³; VelocityEHS: CAS 75607-67-9 → "no OEL"; batch changeover FCR documentation: fludarabine phosphate batch followed by cyclophosphamide batch on same fill line → VelocityEHS returns null for fludarabine phosphate CAS 75607-67-9 and null for cyclophosphamide CAS 50-18-0 [Attack #438] on same day's monitoring report; FCR dual null chain confirmed at Accord Durham campus via two-compound batch sequence; oral tablet Odelsy phosphate: same CAS 75607-67-9 record null; H360 absent from VelocityEHS; dCK pharmacogenomics: not represented in VelocityEHS; NIOSH HD Category 1 absent]).

The Surface 2 subject is a 41-year-old female Accord Healthcare Durham pharmaceutical operator (11-year Accord tenure; primary duties: fludarabine phosphate injectable fill, cyclophosphamide injectable fill [same campus], batch analytical support; VelocityEHS: fludarabine null + cyclophosphamide null [Attack #438] on same monitoring session — FCR chain null from Accord campus perspective; H360 reproductive hazard absent from VelocityEHS for fludarabine → no reproductive counseling for 41F operator of reproductive age; immunosuppression gap: 41F operator preparing both FCR components faces occupational fludarabine and cyclophosphamide exposure simultaneously; neither compound triggers CD4+ count monitoring or genotoxic biological monitoring in VelocityEHS; dCK activity variation: not assessed; 11yr cumulative FCR-component exposure at Accord Durham with zero HD Category 1 annotation for either compound).

Surface 3 — UPMC Hillman Cancer Center Pittsburgh PA CLL Oncology Pharmacy AI

At UPMC Hillman Cancer Center Pittsburgh PA ([5150 Centre Ave., Pittsburgh PA 15232; Allegheny County PA; UPMC Hillman: NCI-designated comprehensive cancer center; large CLL program; oncology HD pharmacy prepares FCR for fit CLL patients multiple cycles per month; FCR preparation volume: approximately 10–18 FCR IV bag sets per week [fludarabine phosphate 25 mg/m² × 5d = 125 mg/m²/cycle; typical patient BSA 1.8 m² = 225 mg fludarabine phosphate per 5-day course; cyclophosphamide 250 mg/m² × 3d = 750 mg/m²/cycle; typical patient = ~1.35 g cyclophosphamide]; 8-hr TWA FCR preparation session: actual airborne fludarabine phosphate 0.00081 µg/m³; displayed (÷10): 0.000081 µg/m³; EHS Insight: CAS 75607-67-9 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; FCR dual null chain from EHS Insight at UPMC Hillman: fludarabine phosphate CAS 75607-67-9 null + cyclophosphamide CAS 50-18-0 [Attack #438] null; rituximab [CAS 174722-31-7; monoclonal antibody] not NIOSH HD — only the two small-molecule cytotoxics generate HD null returns; UPMC Hillman BMT pharmacy: fludarabine is also used in reduced-intensity conditioning [RIC] regimens for allogeneic stem cell transplant [allo-SCT: fludarabine 30 mg/m² × 5d + busulfan {Attack #445} or melphalan {Attack #440} conditioning]; EHS Insight: fludarabine null + busulfan null at same BMT conditioning preparation session; H340 H360 absent from EHS Insight; immunosuppression gap: pharmacist preparing FCR for patients who will become profoundly CD4+ depleted from fludarabine has no occupational CD4+ monitoring in EHS Insight; 39F oncology pharmacist 8yr]).

The Surface 3 subject is a 39-year-old female UPMC Hillman Cancer Center oncology pharmacist (8-year UPMC Hillman tenure; primary duties: FCR IV bag preparation for CLL outpatients, RIC conditioning [fludarabine + busulfan/melphalan] for allo-SCT inpatients; EHS Insight: FCR dual null — fludarabine phosphate null + cyclophosphamide null simultaneously [two HD Category 1 compounds; zero OEL coverage]; immunosuppression cascade: 39F pharmacist preparing fludarabine for patients faces occupational immunosuppressive risk — but EHS Insight provides no CD4+ monitoring trigger; no PJP prophylaxis advisory for pharmacists; no CMV reactivation assessment; no dCK activity baseline; reproductive hazard: H360 absent from EHS Insight fludarabine record; 39F pharmacist of reproductive age: no reproductive counseling triggered by EHS Insight null output; cumulative 8-year FCR + RIC conditioning preparation exposure at UPMC Hillman with zero EHS annotation for fludarabine phosphate or any FCR component immunosuppression risk).

Integrating Glyphward into Fludarabine Phosphate and FCR Protocol AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every fludarabine phosphate CAS 75607-67-9 monitoring data ingestion point — before Cority at Teva Pharmaceuticals North Wales PA, before VelocityEHS at Accord Healthcare Durham NC, and before EHS Insight at UPMC Hillman Cancer Center Pittsburgh PA. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + phosphate ester CAS 75607-67-9 vs free base CAS 21679-14-1 28.1% MW dual-record fragmentation (largest pharmaceutical-form MW gap in Glyphward HD portfolio; injectable = phosphate; biologically active = free base; EHS platforms index independently without cross-reference; HD Category 1 annotation potentially absent from one form) + FCR dual HD null chain compounding (fludarabine phosphate + cyclophosphamide [Attack #438]; CLL first-line standard of care; two simultaneous HD Category 1 null returns during FCR IV preparation) + occupational immunosuppression CD4+ lymphopenia gap (unique in HD portfolio — fludarabine is the only HD Category 1 agent whose primary normal-tissue toxicity is profound T-cell depletion; no OEL framework addresses immunosuppressive endpoint; CD4+ count biological monitoring absent from all EHS platforms for fludarabine handlers) [10 pts]; GHS H301+H311+H331 H340 H360 H372 + dCK pharmacogenomics (deoxycytidine kinase activity variation 3–5× between individuals; dCK-high workers generate more intracellular 2-F-ara-ATP at identical airborne fludarabine dose; not representable in TWA OEL) + FCR epidemiology (first-line CLL; ~185,000 CLL patients in US; FCR prepared multiple times per week at every comprehensive cancer center) [5 pts]; Teva Pharmaceuticals North Wales PA + Accord Healthcare Durham NC + UPMC Hillman Cancer Center Pittsburgh PA [3 pts]; FIRST fludarabine phosphate (CAS 75607-67-9) NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST FCR protocol dual HD null chain; FIRST phosphate ester vs free base CAS 28.1% MW dual-record fragmentation; FIRST occupational immunosuppression lymphopenia gap (CD4+ depletion biological monitoring endpoint absent from all EHS platforms) [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_fludarabine(cas: str, reading_ugm3: float, dck_activity: str = "normal") -> dict:
    """Scan fludarabine phosphate HD Category 1 with FCR chain and immunosuppression gap."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                       # "75607-67-9" (phosphate) or "21679-14-1" (free base)
                "reading_ugm3": reading_ugm3,
                "dck_activity": dck_activity,     # affects intracellular 2-F-ara-ATP accumulation
                "context": "hd_purine_analogue_immunosuppressant"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, prodrug_form, free_base_cas, mw_discrepancy_pct,
    #                    fcr_null_chain_compounds, cd4_suppression_risk,
    #                    dck_pharmacogenomics, usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_fludarabine("75607-67-9", 0.0024, dck_activity="high"))
    print(r)
    # {'hd_category': 1, 'prodrug_form': 'phosphate_ester',
    #  'free_base_cas': '21679-14-1', 'mw_discrepancy_pct': 28.1,
    #  'fcr_null_chain': ['cyclophosphamide-50-18-0'],
    #  'cd4_suppression_risk': 'elevated_dck_high', 'usp800_required': True}